These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 19960346)

  • 1. Targeted proteasome inhibition by Velcade induces apoptosis in human mesothelioma and breast cancer cell lines.
    Wang Y; Rishi AK; Puliyappadamba VT; Sharma S; Yang H; Tarca A; Dou QP; Lonardo F; Ruckdeschel JC; Pass HI; Wali A
    Cancer Chemother Pharmacol; 2010 Aug; 66(3):455-66. PubMed ID: 19960346
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical studies of the proteasome inhibitor bortezomib in malignant pleural mesothelioma.
    Gordon GJ; Mani M; Maulik G; Mukhopadhyay L; Yeap BY; Kindler HL; Salgia R; Sugarbaker DJ; Bueno R
    Cancer Chemother Pharmacol; 2008 Apr; 61(4):549-58. PubMed ID: 17522864
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Curcumin suppresses growth of mesothelioma cells in vitro and in vivo, in part, by stimulating apoptosis.
    Wang Y; Rishi AK; Wu W; Polin L; Sharma S; Levi E; Albelda S; Pass HI; Wali A
    Mol Cell Biochem; 2011 Nov; 357(1-2):83-94. PubMed ID: 21594647
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bortezomib (PS-341, Velcade) increases the efficacy of trastuzumab (Herceptin) in HER-2-positive breast cancer cells in a synergistic manner.
    Cardoso F; Durbecq V; Laes JF; Badran B; Lagneaux L; Bex F; Desmedt C; Willard-Gallo K; Ross JS; Burny A; Piccart M; Sotiriou C
    Mol Cancer Ther; 2006 Dec; 5(12):3042-51. PubMed ID: 17148762
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MDM2 antagonist nutlin plus proteasome inhibitor velcade combination displays a synergistic anti-myeloma activity.
    Saha MN; Jiang H; Jayakar J; Reece D; Branch DR; Chang H
    Cancer Biol Ther; 2010 Jun; 9(11):936-44. PubMed ID: 20418664
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro and in vivo therapeutic efficacy of the PPAR-γ agonist troglitazone in combination with cisplatin against malignant pleural mesothelioma cell growth.
    Hamaguchi N; Hamada H; Miyoshi S; Irifune K; Ito R; Miyazaki T; Higaki J
    Cancer Sci; 2010 Sep; 101(9):1955-64. PubMed ID: 20608936
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BU-32: a novel proteasome inhibitor for breast cancer.
    Agyin JK; Santhamma B; Nair HB; Roy SS; Tekmal RR
    Breast Cancer Res; 2009; 11(5):R74. PubMed ID: 19821999
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Augmenting chemosensitivity of malignant melanoma tumors via proteasome inhibition: implication for bortezomib (VELCADE, PS-341) as a therapeutic agent for malignant melanoma.
    Amiri KI; Horton LW; LaFleur BJ; Sosman JA; Richmond A
    Cancer Res; 2004 Jul; 64(14):4912-8. PubMed ID: 15256463
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Temsirolimus inhibits malignant pleural mesothelioma growth in vitro and in vivo: synergism with chemotherapy.
    Hoda MA; Mohamed A; Ghanim B; Filipits M; Hegedus B; Tamura M; Berta J; Kubista B; Dome B; Grusch M; Setinek U; Micksche M; Klepetko W; Berger W
    J Thorac Oncol; 2011 May; 6(5):852-63. PubMed ID: 21358348
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TRAIL and proteasome inhibitors combination induces a robust apoptosis in human malignant pleural mesothelioma cells through Mcl-1 and Akt protein cleavages.
    Yuan BZ; Chapman J; Ding M; Wang J; Jiang B; Rojanasakul Y; Reynolds SH
    BMC Cancer; 2013 Mar; 13():140. PubMed ID: 23517112
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential apoptotic response to the proteasome inhibitor Bortezomib [VELCADE, PS-341] in Bax-deficient and p21-deficient colon cancer cells.
    Yu J; Tiwari S; Steiner P; Zhang L
    Cancer Biol Ther; 2003; 2(6):694-9. PubMed ID: 14688479
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The proteasome inhibitor bortezomib targets cell cycle and apoptosis and acts synergistically in a sequence-dependent way with chemotherapeutic agents in mantle cell lymphoma.
    Hutter G; Rieken M; Pastore A; Weigert O; Zimmermann Y; Weinkauf M; Hiddemann W; Dreyling M
    Ann Hematol; 2012 Jun; 91(6):847-56. PubMed ID: 22231280
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proteasome stress sensitizes malignant pleural mesothelioma cells to bortezomib-induced apoptosis.
    Cerruti F; Jocollè G; Salio C; Oliva L; Paglietti L; Alessandria B; Mioletti S; Donati G; Numico G; Cenci S; Cascio P
    Sci Rep; 2017 Dec; 7(1):17626. PubMed ID: 29247244
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sequential effects of the proteasome inhibitor bortezomib and chemotherapeutic agents in uterine cervical cancer cell lines.
    Miyamoto Y; Nakagawa S; Wada-Hiraike O; Seiki T; Tanikawa M; Hiraike H; Sone K; Nagasaka K; Oda K; Kawana K; Nakagawa K; Fujii T; Yano T; Kozuma S; Taketani Y
    Oncol Rep; 2013 Jan; 29(1):51-7. PubMed ID: 23064281
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of the proteasome inhibitor bortezomib alone and in combination with chemotherapeutic agents in gastric cancer cell lines.
    Bae SH; Ryoo HM; Kim MK; Lee KH; Sin JI; Hyun MS
    Oncol Rep; 2008 Apr; 19(4):1027-32. PubMed ID: 18357392
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The proteasome inhibitor bortezomib augments anti-proliferative effects of mistletoe lectin-I and the PPAR-gamma agonist rosiglitazone in human melanoma cells.
    Freudlsperger C; Thies A; Pfüller U; Schumacher U
    Anticancer Res; 2007; 27(1A):207-13. PubMed ID: 17352234
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential sensitivity of breast cancer and melanoma cells to proteasome inhibitor Velcade.
    Yerlikaya A; Erin N
    Int J Mol Med; 2008 Dec; 22(6):817-23. PubMed ID: 19020781
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The proteasome inhibitor bortezomib induces apoptosis in human retinoblastoma cell lines in vitro.
    Poulaki V; Mitsiades CS; Kotoula V; Negri J; McMillin D; Miller JW; Mitsiades N
    Invest Ophthalmol Vis Sci; 2007 Oct; 48(10):4706-19. PubMed ID: 17898295
    [TBL] [Abstract][Full Text] [Related]  

  • 19. JQ1, a BET Inhibitor, Synergizes with Cisplatin and Induces Apoptosis in Highly Chemoresistant Malignant Pleural Mesothelioma Cells.
    Zanellato I; Colangelo D; Osella D
    Curr Cancer Drug Targets; 2018; 18(8):816-828. PubMed ID: 28669341
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual targeting of glioblastoma multiforme with a proteasome inhibitor (Velcade) and a phosphatidylinositol 3-kinase inhibitor (ZSTK474).
    Lin L; Gaut D; Hu K; Yan H; Yin D; Koeffler HP
    Int J Oncol; 2014 Feb; 44(2):557-62. PubMed ID: 24297065
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.